CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $231.04M, above the global median of $18.73M
- PositionCurrent ratio is 0.24×, lower than 95% of its Biotechnology peers (median 5.71×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.32BCNY644.35M · vs all stocks (USD)
Revenue (TTM)
1.48BCNY220.87M · vs all stocks (USD)
Profit Margin
-96.41%vs Biotechnology peers
Beta
0.5410xvs all stocks
52-Week Change
-40.42%vs all stocks
Market Capitalization
4.32BCNY644.35M · vs all stocks (USD)
Enterprise Value
5.93BCNY885.39M · vs all stocks (USD)
Forward P/E
22.52xvs Biotechnology peers
Price to Sales (TTM)
2.92xvs Biotechnology peers
Enterprise to Revenue
4.01xvs Biotechnology peers
Enterprise to EBITDA
43.32xvs Biotechnology peers
Gross Margin
29.23%vs Biotechnology peers
Profit Margin
-96.41%vs Biotechnology peers
Operating Margin
-4.24%vs Biotechnology peers
Return on Assets (TTM)
-0.36%vs Biotechnology peers
Revenue (TTM)
1.48BCNY220.87M · vs all stocks (USD)
Revenue per Share (TTM)
2.27CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-12.20%vs Biotechnology peers
Gross Profit (TTM)
434.65MCNY64.86M · vs all stocks (USD)
EBITDA (TTM)
136.95MCNY20.44M · vs all stocks (USD)
Net Income (TTM)
-1.43BCNY-212.95M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-17.19%vs Biotechnology peers
Operating Cash Flow (TTM)
98.15MCNY14.65M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.55BCNY231.04M · vs all stocks (USD)
5-Year Average Dividend Yield
0.82%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
404.27MCNYFY2025 · Dec 31, 2025Revenue
1.60BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.16BCNYFY2025 · Dec 31, 2025Gross Profit
435.94MCNYFY2025 · Dec 31, 2025Operating Income
-76.60MCNY-11.43M · vs all stocks (USD)
Pre-tax Income
-1.34BCNYFY2025 · Dec 31, 2025Income Tax Expense
33.95MCNYFY2025 · Dec 31, 2025Net Income
-1.37BCNYFY2025 · Dec 31, 2025EBIT
-1.05BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-289.75MCNYFY2025 · Dec 31, 2025Research & Development
70.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
155.27MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.11MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
794.99KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
284.06MCNYFY2025 · Dec 31, 2025EPS (Basic)
-2.11CNYFY2025 · Dec 31, 2025EPS (Diluted)
-2.11CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
659.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
659.80MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.37BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-21.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-998.04MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
245.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.37BCNYFY2025 · Dec 31, 2025Other Non-cash Items
290.96MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
40.61MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
41.18MCNYFY2025 · Dec 31, 2025Capital Expenditures
-16.50MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-1.64MCNYFY2025 · Dec 31, 2025Sale of Investments
5.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.54MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
59.60MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-65.93MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-5.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
10.67MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.50MCNYFY2025 · Dec 31, 2025Shares Outstanding
661.28MSharesUpdated Sep 20, 2026Float Shares
479.12MSharesUpdated Sep 20, 2026% Held by Insiders
34.56%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
177.41MCNY26.47M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2710CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.44BCNY214.45M · vs all stocks (USD)
Current Ratio (MRQ)
0.2360xvs Biotechnology peers
Book Value per Share (MRQ)
-0.9590CNYUpdated Sep 20, 2026Total Assets
6.75BCNY1.01B · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
6.70BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
530.23MCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.17BCNYFY2025 · Dec 31, 2025Cash
254.52MCNYFY2025 · Dec 31, 2025Cash Equivalents
51.30KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
254.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
750.42MCNYFY2025 · Dec 31, 2025Inventory
295.43MCNYFY2025 · Dec 31, 2025Accounts Payable
1.19BCNYFY2025 · Dec 31, 2025Short-term Debt
1.00BCNYFY2025 · Dec 31, 2025Other Current Liabilities
43.29MCNYFY2025 · Dec 31, 2025Long-term Debt
464.57MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.61MCNYFY2025 · Dec 31, 2025Common Stock (Book)
661.28MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.23BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
43.95MCNY6.56M · vs all stocks (USD)
Treasury Stock
8.50MCNYFY2025 · Dec 31, 202552-Week Low
5.90CNYUpdated Sep 20, 202652-Week High
11.45CNYUpdated Sep 20, 202652-Week Change
-40.42%vs all stocks
Beta
0.5410xvs all stocks
50-Day MA
6.77CNYUpdated Sep 20, 2026200-Day MA
8.92CNYUpdated Sep 20, 2026Avg 10-Day Volume
9.14MSharesUpdated Sep 20, 2026Avg 30-Day Volume
9.03MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-2.17CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.24×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.24Industry median: 5.71Industry P5: 1.02Peers compared: 260
Financial Health
Altman Z-Score -1.37: distress zoneCritical
Altman Z-Score: -1.37
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $231.04M, above the global median of $18.73MNotable
Levered free cash flow (USD): 231,044,436.035Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Dae-Il Corp.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
MGM Resorts International
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Suzhou Victory Precision Manufacturing Co., Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone